Neurotrophic factor production accelerator

A method for accelerating neurotrophic factor production, which comprises administering, to a mammal, a compound represented by the following formula (I):

• wherein R1 is lower alkyl, aryl, ar(lower)alkoxy or a heterocyclic group, the above groups being optionally substituted by halogen, R2 is a hydrogen atom or lower alkyl, R3 is cyclo(lower)alkyl, aryl or ar(lower)alkyl, the above groups being optionally substituted by halogen, A is —CO—, —SO2— or lower alkylene, X is N or CH, and Y is —CO—, —SO2— or —CONH—, a salt thereof, a prodrug thereof or a solvate thereof.

5-6. (canceled)

A pharmaceutical composition for accelerating neurotrophic factor production, which comprises a compound represented by the following formula (I):

• wherein R1 is lower alkyl, aryl, ar(lower)alkoxy, or a heterocyclic group, the above groups being optionally substituted by halogen, R2 is a hydrogen atom or lower alkyl, R3 is cyclo(lower)alkyl, aryl or ar(lower)alkyl, the above groups being optionally substituted by halogen, A is —CO—, —SO2— or lower alkylene, X is N or CH, and Y is —CO—, —SO2— or —CONH—, a salt thereof, a prodrug thereof or a solvate thereof, and a pharmaceutically acceptable carrier.

An agent for the prophylaxis or treatment of a motor nervous system or peripheral nervous system disease, which comprises, as an active ingredient, a compound having a neurotrophic factor production accelerating activity.

A method of preventing or treating a motor nervous system or peripheral nervous system disease, which comprises administering a compound having a neurotrophic factor production accelerating activity to a mammal.

18-21. (canceled)

A pharmaceutical composition for the prophylaxis or treatment of a motor nervous system or peripheral nervous system disease, which comprises a compound having a neurotrophic factor production accelerating activity and a pharmaceutically acceptable carrier.